Fat loss peptide protocols targeting lipolysis, metabolic rate, and body recomposition. A fragment of growth hormone is rewriting the rules of targeted fat loss, while GLP-1 agonists became a cultural phenomenon by delivering dramatic short-term weight loss — the honest framing is chronic-disease pharmacology: effective while taken, compensation when withdrawn. This hub maps three distinct peptide classes acting on glucose metabolism through different mechanisms, profiles compounds like Retatrutide (the first triple agonist), and includes the MOTS-c exercise-mimetic pathway for metabolic flexibility.
GLP-1 agonism is the headline. The full picture is three distinct peptide classes acting on glucose metabolism through three different mechanisms — and the honest protocol leads with the one that has actually passed regulatory scrutiny.
For the sophisticated health optimizer, the narrative of the last few years has been dominated by the "incretin revolution." We have watched semaglutide and tirzepatide dismantle the traditional "willpower" myth of obesity. Yet, a frustrating biological reality has emerged: the "weight loss wall." Enter Retatrutide — the world's first triple agonist designed to re-engineer the metabolic equation entirely.
A synthetic GHRH analog that tells your pituitary to release its own growth hormone, not inject someone else's.
A selective ghrelin mimetic that triggers your pituitary to release growth hormone without touching cortisol, prolactin, or appetite.
The GLP-1 receptor agonist reshaping metabolic medicine, from weight loss to cardiovascular protection, liver repair, and beyond.
The first dual-action incretin that outpaces single-agonist therapy across weight, glucose, heart failure, and sleep apnoea, while forcing medicine to reckon with the musculoskeletal cost of rapid metabolic transformation.
A 16-amino-acid fragment of human growth hormone engineered to trigger fat metabolism without activating the GH receptor, AOD-9604 cleared early clinical trials for obesity before its pivotal Phase IIb collapsed under a placebo response. Now stripped of FDA Category 2 status and banned by WADA, its most interesting data may be in a direction nobody expected: cartilage repair.
The biochemical cofactors your body needs to support Semaglutide therapy.
The biochemical cofactors your body needs to support Tirzepatide therapy.
The biochemical cofactors your body needs to support AOD-9604 (hGH Fragment 176-191) therapy.